- Home
- IVA vs EBS Comparison
IVA vs EBS Comparison
Compare IVA & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVA
- EBS
- Stock Information
- Founded
- IVA 2011
- EBS 1998
- Country
- IVA France
- EBS United States
- Employees
- IVA N/A
- EBS N/A
- Industry
- IVA Biotechnology: Pharmaceutical Preparations
- EBS Biotechnology: Pharmaceutical Preparations
- Sector
- IVA Health Care
- EBS Health Care
- Exchange
- IVA Nasdaq
- EBS Nasdaq
- Market Cap
- IVA 359.6M
- EBS 393.9M
- IPO Year
- IVA 2020
- EBS 2006
- Fundamental
- Price
- IVA $3.62
- EBS $6.42
- Analyst Decision
- IVA Strong Buy
- EBS Strong Buy
- Analyst Count
- IVA 4
- EBS 3
- Target Price
- IVA $10.50
- EBS $14.33
- AVG Volume (30 Days)
- IVA 22.8K
- EBS 1.4M
- Earning Date
- IVA 03-26-2025
- EBS 05-07-2025
- Dividend Yield
- IVA N/A
- EBS N/A
- EPS Growth
- IVA N/A
- EBS N/A
- EPS
- IVA N/A
- EBS N/A
- Revenue
- IVA $14,591,573.00
- EBS $965,400,000.00
- Revenue This Year
- IVA $15.38
- EBS N/A
- Revenue Next Year
- IVA $24.22
- EBS $16.07
- P/E Ratio
- IVA N/A
- EBS N/A
- Revenue Growth
- IVA N/A
- EBS N/A
- 52 Week Low
- IVA $1.53
- EBS $4.02
- 52 Week High
- IVA $4.05
- EBS $15.10
- Technical
- Relative Strength Index (RSI)
- IVA 58.88
- EBS 57.15
- Support Level
- IVA $3.13
- EBS $6.17
- Resistance Level
- IVA $3.54
- EBS $6.68
- Average True Range (ATR)
- IVA 0.27
- EBS 0.38
- MACD
- IVA 0.02
- EBS -0.01
- Stochastic Oscillator
- IVA 69.66
- EBS 64.91
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.